Eye

Bisphosphonates linked to increased glaucoma risk in osteoporosis patients

January 7, 2025

Clinical impact: Findings highlight the importance of monitoring glaucoma symptoms in osteoporosis patients prescribed bisphosphonates. Regular ophthalmologic evaluations may help detect early signs of glaucoma and mitigate potential vision loss.

Study details: This case-control study analyzed medical records of osteoporosis patients to evaluate the risk of developing glaucoma associated with bisphosphonate use. Cases of glaucoma were identified and matched with controls based on age, sex, and duration of osteoporosis.

Results: Bisphosphonate users had a higher likelihood of developing acute angle closure glaucoma (AAC) compared with non-users (adjusted incidence rate ratio [IRR], 1.78; 95% CI, 1.05-3.01). Risedronate was associated with a higher risk of AAC compared with other bisphosphonate formulations (adjusted IRR, 2.12; 95% CI, 1.05-3.01). No significant association was seen between bisphosphonate use and risk of developing open angle glaucoma.

Source:

He B, et al. (2024, December 27). Eye. Risk of glaucoma with bisphosphonate use in patients with osteoporosis: a case-control study. https://pubmed.ncbi.nlm.nih.gov/39730976/